New Partnership in Switzerland

Helsinki – July 8, 2021 – MVision AI, the cloud-based software service provider for radiotherapy treatment planning, today announces that the company has entered into a distribution partnership agreement with the Swiss provider of products and services for optimization of medical equipment, intellimed. Together, intellimed and MVision AI will work to offer, promote, sell, and support the MVision solutions. Intellimed provides advice and support for numerous medical centers, radiology services, private clinics, and public hospitals. 

“intellimed is committed to work with trustworthy companies that are pioneers in their field. This is why we are proud to be the swiss distributor for the MVision’s automatic segmentation solution in radiotherapy. Our partnership results from a common vision: artificial intelligence supporting doctors in their work by allowing them to gain speed and efficiency on a daily basis. Competence, trust and reactivity are what define the collaboration we have with Mvision and we are looking forward to our future projects,” said intellimeds co-founders, Rachel Unell and Jean-Pierre Van Den Bussche.

Mahmudul Hasan, CEO and co-founder of MVision AI, provided further explanation on the topic, “MVision’s guideline based AI segmentation is helping hospitals all over EU to standardize contouring process, and we are excited to bring this to our Swiss customers with this new partnership with intellimed.” 

Artificial intelligence in medicine is a growing field that is improving the lives of both hospitals and patients worldwide. MVision’s deep learning platform helps provide the best radiotherapy treatment possible with consistent quality contouring. MVision’s AI-powered Saas follows official consensus guidelines, delivers 3D organ models within minutes, and is GDPR compliant. The adept, intellimed offers products and services for a variety of customers who wish to invest in the optimization of their medical equipment and resources. Intellimed team is working closely with MVision AI’s expert team to provide reliable, high-quality and confidential services in the most timely manner to cancer clinics throughout Switzerland. 

For further information on intellimed:

Website: www.intellimed.ch 

Tel: +41 79 479 62 72

LinkedIn: https://www.linkedin.com/company/intellimed-switzerland/about/ 

To learn more about MVison AI: 

c/o Terkko Health Hub, Haartmaninkatu 4, 00290 Helsinki, Finland.

Tel: +358 (0) 40 5489 229

Email: info@ mvision.ai

For media inquiries:

Tel: +358 40 500 7915

Email: pr@mvision.ai

 

Our Newsletter

Subscribe to get information, latest news and other interesting offers about MVision AI

Related Posts

20.11.2024

MVision AI Ranked Among the Top 10 in Deloitte Technology Fast 50 Finland for 2024

Helsinki, Finland, 20 November 2024 – MVision AI, a leading innovator in AI-driven solutions for oncology, is proud to announce its recognition among the top ten companies in the Deloitte Technology Fast 50 Finland 2024 ranking. This prestigious award acknowledges MVision AI's rapid growth and its mission-driven advancements in making…

Press Releases

7.11.2024

Safe and Ethical AI in Radiation Oncology: Regulations and MVision’s Compliance

Technology is evolving, and the same applies to Radiation Oncology. New ways and new tools require new rules. Artificial intelligence (AI)  brings tremendous potential, so the world has to learn how to get the best of it, safely.  Al systems identified as high-risk have to comply with strict requirements, including…

Articles

24.10.2024

MVision AI Secures FDA 510(k) Clearance for Contour+ Advanced CT and MR Models

Helsinki, October 2024 – MVision AI, a leading innovator in AI-powered solutions for radiotherapy, is thrilled to announce that its auto-contouring solution Contour+ has received FDA 510(k) clearance for three new models: Bones CT, Brain MR, and Male Pelvis MR T2, and five updated models: Brain CT, Abdomen & Lung…

Press Releases